Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$0.46
$0.43
$0.19
$1.24
$16.71M1.85661,416 shs351,642 shs
I-Mab stock logo
IMAB
I-Mab
$2.80
+14.3%
$0.98
$0.60
$3.07
$228.65M1.17349,700 shs2.11 million shs
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$2.34
-0.8%
$2.29
$1.90
$4.21
$67.54M0.7171,815 shs205,640 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.10
-1.3%
$19.15
$12.12
$26.99
$51.44M0.5923,339 shs716 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00%0.00%0.00%0.00%0.00%
I-Mab stock logo
IMAB
I-Mab
0.00%+88.46%+178.41%+201.72%+30.32%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
0.00%-6.35%+5.36%-10.94%-37.73%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
0.00%+5.57%-19.86%+11.99%-2.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
I-Mab stock logo
IMAB
I-Mab
2.5444 of 5 stars
3.73.00.00.01.71.70.6
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
0.7683 of 5 stars
0.03.00.00.00.61.71.3
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
2.6764 of 5 stars
3.55.00.00.03.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00
N/AN/AN/A
I-Mab stock logo
IMAB
I-Mab
3.33
Buy$5.5096.43% Upside
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4.00
Strong BuyN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50120.50% Upside

Current Analyst Ratings Breakdown

Latest CEMI, VTVT, IMAB, and VTGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
4/4/2025
I-Mab stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
4/4/2025
I-Mab stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$48.34M0.35N/AN/A$0.48 per share0.95
I-Mab stock logo
IMAB
I-Mab
$3.27M69.86N/AN/A$2.93 per share0.96
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$698K96.76N/AN/A$2.81 per share0.83
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$17K3,025.85N/AN/A($9.27) per share-1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
-$23.29M-$1.20N/AN/A-47.03%-113.57%-38.22%N/A
I-Mab stock logo
IMAB
I-Mab
-$206.44MN/A0.00N/AN/AN/AN/AN/A8/27/2025 (Estimated)
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$20.25M-$3.01N/AN/AN/A-184.64%-47.29%8/6/2025 (Estimated)

Latest CEMI, VTVT, IMAB, and VTGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/10/2025Q4 2025
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$0.53N/AN/AN/A$0.18 millionN/A
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
3/20/2025Q4 2024
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.87-$0.55+$0.32-$0.55N/A$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/A
I-Mab stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/A
1.23
1.04
I-Mab stock logo
IMAB
I-Mab
N/A
15.99
15.99
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/A
9.35
9.35
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
6.69
6.69

Institutional Ownership

CompanyInstitutional Ownership
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
8.65%
I-Mab stock logo
IMAB
I-Mab
38.38%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
78.39%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
3.30%
I-Mab stock logo
IMAB
I-Mab
22.10%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
1.29%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
33736.73 million35.51 millionNot Optionable
I-Mab stock logo
IMAB
I-Mab
38081.66 million63.49 millionOptionable
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4028.86 million28.49 millionOptionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.20 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chembio Diagnostics stock logo

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.80 +0.35 (+14.29%)
Closing price 04:00 PM Eastern
Extended Trading
$2.84 +0.04 (+1.43%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Vistagen Therapeutics stock logo

Vistagen Therapeutics NASDAQ:VTGN

$2.34 -0.02 (-0.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.08 (+3.42%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.10 -0.21 (-1.29%)
Closing price 03:58 PM Eastern
Extended Trading
$16.10 0.00 (0.00%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.